Feifei Tang

Beijing Key Laboratory Of Cell And Gene Therapy For Hematologic Malignancies
Beijing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Enhanced prognosis of acute myeloid leukaemia patients with dmCEBPAbZIP -inf mutations: Insights from a multicentre Chinese cohort study.

Enhanced prognosis of acute myeloid leukaemia patients with dmCEBPAbZIP -inf mutations: Insights from a multicentre Chinese cohort study.

Journal: British journal of haematology
Published: May 22, 2026

Conditioning dose adjustment in obese adult patients with severe aplastic anemia undergoing haploidentical hematopoietic stem cell transplantation: a propensity score-matched analysis.

Conditioning dose adjustment in obese adult patients with severe aplastic anemia undergoing haploidentical hematopoietic stem cell transplantation: a propensity score-matched analysis.

Journal: Bone marrow transplantation
Published: February 09, 2026

Venetoclax and azacitidine versus CAG for unfit patients with newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.

Venetoclax and azacitidine versus CAG for unfit patients with newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.

Journal: Leukemia research
Published: November 15, 2025

Co-Mutation of ASXL1 and KRAS Defines a Novel Ultra-Adverse-Risk Subtype of Acute Myeloid Leukemia in a Large-Scale Cohort.

Co-Mutation of ASXL1 and KRAS Defines a Novel Ultra-Adverse-Risk Subtype of Acute Myeloid Leukemia in a Large-Scale Cohort.

Journal: Cancer medicine
Published: September 24, 2025

Prognostic covariates associated with outcomes in patients with NPM1-mutated acute myeloid leukemia.

Prognostic covariates associated with outcomes in patients with NPM1-mutated acute myeloid leukemia.

Journal: The oncologist
Published: July 17, 2025

IKZF1 Variants Predicted Poor Outcomes in Acute Myeloid Leukemia Patients with CEBPA bZIP In-Frame Mutations.

IKZF1 Variants Predicted Poor Outcomes in Acute Myeloid Leukemia Patients with CEBPA bZIP In-Frame Mutations.

Journal: Cancers
Published: June 09, 2025

KDM6A Variants Increased Relapse Risk in Adult Acute Myeloid Leukemia.

KDM6A Variants Increased Relapse Risk in Adult Acute Myeloid Leukemia.

Journal: Cancers
Published: June 04, 2025

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Study in Chinese Patients.

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Study in Chinese Patients.

Journal: Cancers
Published: January 09, 2025

Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases.

Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases.

Journal: Frontiers in medicine
Published: December 12, 2024

The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China.

The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China.

Journal: Science China. Life sciences
Published: November 24, 2024

Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia.

Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia.

Journal: Annals of hematology
Published: August 05, 2024

Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3mut acute myeloid leukemia.

Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3mut acute myeloid leukemia.

Journal: Leukemia research
Published: June 19, 2024
Showing 1-12 of 29

Last Updated: 09/26/2026